Inhibition of thromboxane synthesis attenuates insulin hypertension in rats

Henry L. Keen, Michael W. Brands, Manis J. Smith, Eugene W. Shek, John E. Hall

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Chronic insulin infusion in rats increases mean arterial pressure (MAP) and reduces glomerular filtration rate (GFR), but the mechanisms for these actions are not known. This study tested whether thromboxane synthesis inhibition (TSI) would attenuate the renal and blood pressure responses to sustained hyperinsulinemia. Male Sprague-Dawley rats were instrumented with arterial and venous catheters, and MAP was measured 24 h/day. After 4 days of baseline measurements, endogenous synthesis of thromboxane was suppressed in 7 rats by infusing the thromboxane synthetase inhibitor, U63557A, intravenously (30 μg/kg/min) for the remainder of the experiment; 7 other rats received vehicle. Baseline MAP was not significantly different between vehicle and TSI rats (96 ± 1 υ 99 ± 1 mm Hg). After 3 days of U63557A or vehicle, a 5-day control period was started, followed by a 7-day infusion of insulin (1.5 mU/kg/min, intravenously). Glucose (22 mg/kg/min, intravenously) was infused along with insulin to prevent hypoglycemia. In the control period, MAP was not different between vehicle and TSI rats (99 ± 2 v 100 ± 1 mm Hg), but MAP increased throughout the 7-day infusion period only in the vehicle rats with an average increase in blood pressure of 7 ± 2 mm Hg. In the control period, GFR was lower in vehicle rats compared with TSI rats (2.5 ± 0.1 v 3.1 ± 0.2 mL/min, P = .06), and the decrease to 81% ± 4% and 91% ± 6% of control, respectively, during insulin was significant only in the vehicle rats. All variables returned toward control during a 6-day recovery period. These results suggest that full expression of hypertension and renal vasoconstriction during hyperinsulinemia in rats is dependent on a normal ability to synthesize thromboxane.

Original languageEnglish (US)
Pages (from-to)1125-1131
Number of pages7
JournalAmerican journal of hypertension
Volume10
Issue number10 I
DOIs
StatePublished - Oct 1 1997

Fingerprint

Thromboxanes
Insulin
Hypertension
Arterial Pressure
Hyperinsulinism
Glomerular Filtration Rate
Thromboxane-A Synthase
Blood Pressure
Renal Hypertension
Vasoconstriction
Hypoglycemia
Sprague Dawley Rats
Catheters
Kidney
Glucose

Keywords

  • Blood pressure
  • Hypertension
  • Insulin
  • Thromboxane

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Inhibition of thromboxane synthesis attenuates insulin hypertension in rats. / Keen, Henry L.; Brands, Michael W.; Smith, Manis J.; Shek, Eugene W.; Hall, John E.

In: American journal of hypertension, Vol. 10, No. 10 I, 01.10.1997, p. 1125-1131.

Research output: Contribution to journalArticle

Keen, Henry L. ; Brands, Michael W. ; Smith, Manis J. ; Shek, Eugene W. ; Hall, John E. / Inhibition of thromboxane synthesis attenuates insulin hypertension in rats. In: American journal of hypertension. 1997 ; Vol. 10, No. 10 I. pp. 1125-1131.
@article{015d45e940d5437b80e890b9911feab0,
title = "Inhibition of thromboxane synthesis attenuates insulin hypertension in rats",
abstract = "Chronic insulin infusion in rats increases mean arterial pressure (MAP) and reduces glomerular filtration rate (GFR), but the mechanisms for these actions are not known. This study tested whether thromboxane synthesis inhibition (TSI) would attenuate the renal and blood pressure responses to sustained hyperinsulinemia. Male Sprague-Dawley rats were instrumented with arterial and venous catheters, and MAP was measured 24 h/day. After 4 days of baseline measurements, endogenous synthesis of thromboxane was suppressed in 7 rats by infusing the thromboxane synthetase inhibitor, U63557A, intravenously (30 μg/kg/min) for the remainder of the experiment; 7 other rats received vehicle. Baseline MAP was not significantly different between vehicle and TSI rats (96 ± 1 υ 99 ± 1 mm Hg). After 3 days of U63557A or vehicle, a 5-day control period was started, followed by a 7-day infusion of insulin (1.5 mU/kg/min, intravenously). Glucose (22 mg/kg/min, intravenously) was infused along with insulin to prevent hypoglycemia. In the control period, MAP was not different between vehicle and TSI rats (99 ± 2 v 100 ± 1 mm Hg), but MAP increased throughout the 7-day infusion period only in the vehicle rats with an average increase in blood pressure of 7 ± 2 mm Hg. In the control period, GFR was lower in vehicle rats compared with TSI rats (2.5 ± 0.1 v 3.1 ± 0.2 mL/min, P = .06), and the decrease to 81{\%} ± 4{\%} and 91{\%} ± 6{\%} of control, respectively, during insulin was significant only in the vehicle rats. All variables returned toward control during a 6-day recovery period. These results suggest that full expression of hypertension and renal vasoconstriction during hyperinsulinemia in rats is dependent on a normal ability to synthesize thromboxane.",
keywords = "Blood pressure, Hypertension, Insulin, Thromboxane",
author = "Keen, {Henry L.} and Brands, {Michael W.} and Smith, {Manis J.} and Shek, {Eugene W.} and Hall, {John E.}",
year = "1997",
month = "10",
day = "1",
doi = "10.1016/S0895-7061(97)00217-3",
language = "English (US)",
volume = "10",
pages = "1125--1131",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "10 I",

}

TY - JOUR

T1 - Inhibition of thromboxane synthesis attenuates insulin hypertension in rats

AU - Keen, Henry L.

AU - Brands, Michael W.

AU - Smith, Manis J.

AU - Shek, Eugene W.

AU - Hall, John E.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Chronic insulin infusion in rats increases mean arterial pressure (MAP) and reduces glomerular filtration rate (GFR), but the mechanisms for these actions are not known. This study tested whether thromboxane synthesis inhibition (TSI) would attenuate the renal and blood pressure responses to sustained hyperinsulinemia. Male Sprague-Dawley rats were instrumented with arterial and venous catheters, and MAP was measured 24 h/day. After 4 days of baseline measurements, endogenous synthesis of thromboxane was suppressed in 7 rats by infusing the thromboxane synthetase inhibitor, U63557A, intravenously (30 μg/kg/min) for the remainder of the experiment; 7 other rats received vehicle. Baseline MAP was not significantly different between vehicle and TSI rats (96 ± 1 υ 99 ± 1 mm Hg). After 3 days of U63557A or vehicle, a 5-day control period was started, followed by a 7-day infusion of insulin (1.5 mU/kg/min, intravenously). Glucose (22 mg/kg/min, intravenously) was infused along with insulin to prevent hypoglycemia. In the control period, MAP was not different between vehicle and TSI rats (99 ± 2 v 100 ± 1 mm Hg), but MAP increased throughout the 7-day infusion period only in the vehicle rats with an average increase in blood pressure of 7 ± 2 mm Hg. In the control period, GFR was lower in vehicle rats compared with TSI rats (2.5 ± 0.1 v 3.1 ± 0.2 mL/min, P = .06), and the decrease to 81% ± 4% and 91% ± 6% of control, respectively, during insulin was significant only in the vehicle rats. All variables returned toward control during a 6-day recovery period. These results suggest that full expression of hypertension and renal vasoconstriction during hyperinsulinemia in rats is dependent on a normal ability to synthesize thromboxane.

AB - Chronic insulin infusion in rats increases mean arterial pressure (MAP) and reduces glomerular filtration rate (GFR), but the mechanisms for these actions are not known. This study tested whether thromboxane synthesis inhibition (TSI) would attenuate the renal and blood pressure responses to sustained hyperinsulinemia. Male Sprague-Dawley rats were instrumented with arterial and venous catheters, and MAP was measured 24 h/day. After 4 days of baseline measurements, endogenous synthesis of thromboxane was suppressed in 7 rats by infusing the thromboxane synthetase inhibitor, U63557A, intravenously (30 μg/kg/min) for the remainder of the experiment; 7 other rats received vehicle. Baseline MAP was not significantly different between vehicle and TSI rats (96 ± 1 υ 99 ± 1 mm Hg). After 3 days of U63557A or vehicle, a 5-day control period was started, followed by a 7-day infusion of insulin (1.5 mU/kg/min, intravenously). Glucose (22 mg/kg/min, intravenously) was infused along with insulin to prevent hypoglycemia. In the control period, MAP was not different between vehicle and TSI rats (99 ± 2 v 100 ± 1 mm Hg), but MAP increased throughout the 7-day infusion period only in the vehicle rats with an average increase in blood pressure of 7 ± 2 mm Hg. In the control period, GFR was lower in vehicle rats compared with TSI rats (2.5 ± 0.1 v 3.1 ± 0.2 mL/min, P = .06), and the decrease to 81% ± 4% and 91% ± 6% of control, respectively, during insulin was significant only in the vehicle rats. All variables returned toward control during a 6-day recovery period. These results suggest that full expression of hypertension and renal vasoconstriction during hyperinsulinemia in rats is dependent on a normal ability to synthesize thromboxane.

KW - Blood pressure

KW - Hypertension

KW - Insulin

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0030666906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030666906&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(97)00217-3

DO - 10.1016/S0895-7061(97)00217-3

M3 - Article

C2 - 9370383

AN - SCOPUS:0030666906

VL - 10

SP - 1125

EP - 1131

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 10 I

ER -